| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
Purity: ≥98%
DMX-5804 is a novel, potent, orally bioactive and selective MAP4K4 (Mitogen-activated protein kinase kinase kinase kinase-4) inhibitor with an IC50 of 3 nM, a pIC50 of 8.55 for human MAP4K4, less potent on MINK1/MAP4K6 (pIC50, 8.18), and TNIK/MAP4K7 (pIC50, 7.96). In mice, DMX-5804 reduces ischemia-reperfusion injury and improves cardiomyocyte survival. Human failing hearts and pertinent rodent models both activate the protein kinase kinase kinase kinase MAP4K4 (MAP4K4). We show that MAP4K4 is necessary for oxidative stress-induced death using human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) and gene silencing.
| Targets |
MAP4K4 (IC50 = 3 nM); MAP4K4 (pIC50 = 8.55); MINK1/MAP4K6 (pIC50 = 8.18); TNIK/MAP4K7 (pIC50 = 7.96); GCK/MAP4K2 (pIC50 = 6.50); KHS/MAP4K5 (pIC50 = 6.36); GLK/MAP4K3 (pIC50 = 4.95 nM); MLK1/MAP3K9 (pIC50 = 7.19); MLK3/MAP3K11 (pIC50 = 6.99); NUAK (pIC50 = 6.88); VEGFR (pIC50 = 5.72); ABL1 (pIC50 = 5.80 nM); Aurora B (pIC50 = 5.49 nM); FLT3 (pIC50 = 5.31); GSK3β (pIC50 = 4.66)
|
|---|---|
| ln Vitro |
DMX-5804 exhibits great selectivity at MAP4K4 over other kinases, such as GCK/MAP4K2 (pIC50, 6.50), GLK/MAP4K3 (pIC50, 4.95), GSK3β (pIC50, 4.66), KHS/MAP4K5 (pIC50, 6.36), MLK1/MAP3K9 (pIC50, 7.19), MLK3/MAP3K11 (pIC50, 6.99), NUAK (pIC50, 6.88) and VEGFR (pIC50, 5.72), ABL1 (pIC50, 5.80), Aurora B (pIC50, 5.49), FLT3 (pIC50, 5.31)[1].
|
| References |
| Molecular Formula |
C21H19N3O3
|
|---|---|
| Molecular Weight |
361.393864870071
|
| Exact Mass |
361.14
|
| Elemental Analysis |
C, 69.79; H, 5.30; N, 11.63; O, 13.28
|
| CAS # |
2306178-56-1
|
| Related CAS # |
2306178-56-1
|
| PubChem CID |
137334091
|
| Appearance |
Off-white to yellow solid powder
|
| LogP |
2.9
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
27
|
| Complexity |
527
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
FUSHFOGORKZNNQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H19N3O3/c1-26-11-12-27-17-9-7-15(8-10-17)18-13-24(16-5-3-2-4-6-16)20-19(18)21(25)23-14-22-20/h2-10,13-14H,11-12H2,1H3,(H,22,23,25)
|
| Chemical Name |
5-[4-(2-methoxyethoxy)phenyl]-7-phenyl-3H-pyrrolo[2,3-d]pyrimidin-4-one
|
| Synonyms |
DMX-5804; DMX 5804; DMX5804
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 72~125 mg/mL (199.2~345.9 mM)
Ethanol: ~1.5 mg/mL (~4.2 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.76 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.76 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (5.76 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7671 mL | 13.8355 mL | 27.6709 mL | |
| 5 mM | 0.5534 mL | 2.7671 mL | 5.5342 mL | |
| 10 mM | 0.2767 mL | 1.3835 mL | 2.7671 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
MAP4K4 Inhibition Promotes Survival of Human Stem Cell-Derived Cardiomyocytes and Reduces Infarct Size In Vivo.Cell Stem Cell.2019 Apr 4;24(4):579-591.e12. |
Selective Small-Molecule Inhibitors of MAP4K4 Created by Field-Point Modeling and ScreeningIn Silico.Cell Stem Cell.2019 Apr 4;24(4):579-591.e12. |
MAP4K4 Inhibition Reduces Infarct Size in Mice.Cell Stem Cell.2019 Apr 4;24(4):579-591.e12. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
